Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LLY

Lilly(Eli) & Co

Dec 11 • 03:24PM ET

798.70

Dollar change -0.88
Percentage change -0.11	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE MRK JNJ BMY GILD AMGN ABBV REGN BIIB VRTX

| Held by: VTI VOO SPY VUG IVV XLV IWF VHT QUAL IVW

Scroll to Statements

Index	S&P 500	P/E	87.37	EPS (ttm)	9.14	Insider Own	10.39%	Shs Outstand	950.22M	Perf Week	-3.75%
Market Cap	758.22B	Forward P/E	35.35	EPS next Y	22.59	Insider Trans	-0.98%	Shs Float	850.67M	Perf Month	-4.05%
Income	8.37B	PEG	2.70	EPS next Q	5.48	Inst Own	72.77%	Short Float	0.69%	Perf Quarter	-14.58%
Sales	40.86B	P/S	18.55	EPS this Y	110.34%	Inst Trans	5.54%	Short Ratio	1.61	Perf Half Y	-7.91%
Book/sh	14.99	P/B	53.30	EPS next Y	69.97%	ROA	12.54%	Short Interest	5.84M	Perf Year	36.75%
Cash/sh	3.71	P/C	215.50	EPS next 5Y	32.30%	ROE	65.75%	52W Range	561.65 - 972.53	Perf YTD	37.02%
Dividend Est.	5.34 (0.67%)	P/FCF	541.66	EPS past 5Y	13.74%	ROI	19.34%	52W High	-17.87%	Beta	0.40
Dividend TTM	5.20 (0.65%)	Quick Ratio	0.97	Sales past 5Y	9.91%	Gross Margin	80.91%	52W Low	42.21%	ATR (14)	21.82
Dividend Ex-Date	Feb 14, 2025	Current Ratio	1.27	EPS Y/Y TTM	68.88%	Oper. Margin	35.33%	RSI (14)	46.88	Volatility	2.32% 2.52%
Employees	43000	Debt/Eq	2.19	Sales Y/Y TTM	27.41%	Profit Margin	20.48%	Recom	1.53	Target Price	1008.45
Option/Short	Yes / Yes	LT Debt/Eq	2.04	EPS Q/Q	1780.56%	Payout	77.91%	Rel Volume	0.59	Prev Close	799.58
Sales Surprise	-5.44%	EPS Surprise	-16.97%	Sales Q/Q	20.43%	Earnings	Oct 30 BMO	Avg Volume	3.62M	Price	798.70
SMA20	1.89%	SMA50	-4.86%	SMA200	-4.74%	Trades		Volume	1,941,205	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Buy	$997
Nov-15-24	Initiated	Wolfe Research	Outperform	$1000
Oct-17-24	Initiated	Bernstein	Outperform	$1100
Sep-13-24	Resumed	Citigroup	Buy	$1060
Aug-12-24	Upgrade	Deutsche Bank	Hold → Buy	$1025
Feb-21-24	Downgrade	DZ Bank	Buy → Hold	$820
Feb-16-24	Reiterated	Morgan Stanley	Overweight	$805 → $950
Dec-21-23	Downgrade	Daiwa Securities	Buy → Outperform	$660 → $610
Nov-09-23	Initiated	Deutsche Bank	Hold	$535
Oct-20-23	Resumed	UBS	Buy	$612 → $710
Aug-09-23	Upgrade	Jefferies	Hold → Buy	$408 → $615
Jul-26-23	Reiterated	Citigroup	Buy	$360 → $525
Jul-14-23	Initiated	HSBC Securities	Buy	$560
May-24-23	Reiterated	UBS	Buy	$447 → $498
May-24-23	Reiterated	BofA Securities	Buy	$450 → $500
Mar-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$360 → $375
Mar-06-23	Initiated	Jefferies	Hold	$290
Feb-15-23	Downgrade	Societe Generale	Hold → Sell
Nov-18-22	Initiated	Credit Suisse	Outperform	$395
Sep-22-22	Upgrade	UBS	Neutral → Buy	$335 → $363

Show Previous Ratings

Today 02:43PM	Is Eli Lilly Stock A Buy After Zepbound Bests Wegovy In A Head-To-Head Study? (Investor's Business Daily)
01:19PM	Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900 (Insider Monkey)
11:28AM	Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients (Benzinga)
11:24AM	What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction (Quartz)
11:13AM	Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats (Barrons.com)
09:50AM	Loading…
09:50AM	Ro partners with Eli Lilly to expand access to Zepbound vials (Yahoo Finance)
08:15AM	Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer (PR Newswire)
08:00AM	Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound (Quartz)
06:21AM	With new data, Lilly sets pace for next wave of breast cancer drugs (BioPharma Dive)
05:52AM	Lillys £279m bet aims to boost UK life sciences sector (Pharmaceutical Technology)
05:45AM	BenevolentAI restructures; Lilly preps $15B buyback program (BioPharma Dive)
03:00AM	GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration? (Pharma Voice)
Dec-10-24 06:28PM	Asian Stocks Set for Sluggish Start as CPI Looms: Markets Wrap (Bloomberg)
05:37PM	BofA downgrades Moderna, says it's 'tough time' to be vaccine maker (Yahoo Finance Video)
03:48PM	Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump (Reuters)
11:52AM	Loading…
11:52AM	What's Going On With Eli Lilly Stock On Tuesday? (Benzinga)
09:40AM	BofA reinstates pharma coverage (Investing.com)
09:00AM	Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
05:00AM	Swiss Re Says Too Early to Tell if Obesity Drugs Will Reshape Insurance (The Wall Street Journal)
04:10AM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
Dec-09-24 05:45PM	Phase 3 results for Lilly's Jaypirca (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting (PR Newswire)
05:29PM	Toll Brothers, Eli Lilly, Amazon & Intuit: After-Hours Movers (Yahoo Finance Video)
04:46PM	Lilly Approves $15 Billion in Share Buybacks, Raises Dividend (Bloomberg)
04:17PM	Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase (PR Newswire)
12:44PM	Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue (Barrons.com)
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
09:00AM	CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses Parade (PR Newswire)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
04:59AM	Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now (Motley Fool)
Dec-08-24 09:14PM	Apple Tops the List of Best-Managed Companies of 2024 (The Wall Street Journal)
04:39PM	Loading…
Dec-07-24 04:39PM	Billionaire Asness Sold Cisco Systems (CSCO) and Bought Eli Lilly and Company (LLY) (Insider Monkey)
06:46AM	3 No-Brainer Growth Stocks to Buy in December (Motley Fool)
03:52AM	Why Is Eli Lilly and Company (LLY) Among the Best Dividend Stocks to Invest In Now? (Insider Monkey)
03:15AM	Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says. (Motley Fool)
Dec-06-24 01:42PM	Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility (Benzinga)
01:38PM	New study finds obesity costs US industry $347bn a year (Pharmaceutical Technology)
01:38PM	Nature study finds obesity costs US industry $347bn a year (Pharmaceutical Technology)
10:34AM	Eli Lilly to invest $3bn in Wisconsin facility expansion (Pharmaceutical Technology)
06:49AM	Lilly adds to obesity drug production push with $3B investment (BioPharma Dive)
05:47AM	Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street (Motley Fool)
05:00AM	Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup (Quartz)
Dec-05-24 06:02PM	Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage (CNBC TV)
05:35PM	Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments (The Wall Street Journal)
05:26PM	Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound (Associated Press Finance)
03:40PM	Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars (Reuters)
03:30PM	Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin (PR Newswire)
09:10AM	The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials (GuruFocus.com)
08:00AM	The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market (Investor's Business Daily)
07:00AM	Eli Lilly announces topline results from SURMOUNT-5 trial (TipRanks)
06:52AM	Bitcoin Is Soaring for This Reason. Why Investors Should Beware the Crypto Rally and 5 Other Things to Know Today. (Barrons.com)
05:32AM	This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy? (Motley Fool)
Dec-04-24 04:20PM	Eli Lillys Weight-Loss Drug Zepbound More Effective than Novos Wegovy, Study Shows (Barrons.com)
04:02PM	Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk (Investor's Business Daily)
01:41PM	Analyst Report: Eli Lilly and Company (Morningstar Research)
01:05PM	Lillys Zepbound wins the weight loss duel with Novos Wegovy (Clinical Trials Arena)
11:59AM	Eli Lilly stock pops: Wegovy beats Novo Nordisk rival drug in study (Yahoo Finance Video)
11:42AM	Eli Lilly's Weight-Loss Breakthrough: Zepbound Crushes Rivals, Stock Soars Nearly 44% YTD (GuruFocus.com)
11:15AM	Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial (Investopedia)
10:28AM	Eli Lillys Zepbound Beats Novo Nordisks Wegovy in First Head-to-Head Study (The Wall Street Journal)
10:21AM	Zepbound tops Wegovy for weight loss in Eli Lilly study (Associated Press Finance)
09:41AM	Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study (Quartz)
09:26AM	Eli Lilly says Zepbound is 'superior' to rival weight loss drug Wegovy (Quartz)
08:16AM	Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trial (Investing.com)
07:16AM	Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial (Investor's Business Daily)
07:14AM	Eli Lilly stock higher following surprise weight loss treatment data (TheStreet)
07:10AM	Eli Lilly Just Got a Bundle of Good News: Time to Buy? (Motley Fool)
06:45AM	Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% (PR Newswire)
Dec-03-24 08:23PM	Lightning Round: I prefer Eli Lilly over Regeneron (CNBC TV)
Dec-02-24 01:22PM	Four oral GLP-1R products in Phase III trials as race intensifies (Clinical Trials Arena)
12:19PM	Diabetes advocacy group discourages use of compounded GLP-1 drugs (BioPharma Dive)
11:22AM	Why Is Eli Lilly and Company (LLY) Among Ken Fishers Top Stock Picks Heading Into 2025? (Insider Monkey)
07:45AM	Analyst Report: Eli Lilly and Company (Morningstar Research)
Dec-01-24 04:27PM	Why Is Eli Lilly and Company (LLY) Among Louis Navelliers Top Stock Picks Heading Into 2025? (Insider Monkey)
Nov-30-24 07:00AM	Eli Lilly and Novo Nordisks Obesity Moat Just Got Stronger (The Wall Street Journal)
Nov-29-24 04:28PM	The Score: GM, Macys, Novo Nordisk and More Stocks That Defined the Week (The Wall Street Journal)
11:36AM	Galderma Bets on Skin Drug to Turn Around Pharma Business (The Wall Street Journal)
11:31AM	Why Is Lilly (LLY) Down 5% Since Last Earnings Report? (Zacks)
09:00AM	Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:30AM	Radiopharmaceutical trials face extra complexities due to nuclear red tape (Clinical Trials Arena)
Nov-28-24 07:30AM	Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock? (Motley Fool)
Nov-27-24 02:37PM	Calls of the Day: Martin Marietta, Datadog, Bristol-Myers, Eli Lilly and Disney (CNBC TV)
12:44PM	MHRA approves Eli Lillys Alzheimers diagnostic imaging agent Tauvid (Medical Device Network)
12:17PM	The race for approval: oral GLP-1R therapies in obesity (Pharmaceutical Technology)
04:35AM	The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now (Motley Fool)
03:57AM	Why Amgen's Weight Loss Result Is a Win for Eli Lilly (Motley Fool)
Nov-26-24 05:16PM	Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment (Investor's Business Daily)
04:51PM	S&P 500 Gains and Losses Today: NRG Energy Stock Surges After Analyst Upgrade (Investopedia)
03:41PM	White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs (The Wall Street Journal)
02:23PM	Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy? (Investor's Business Daily)
02:18PM	Novo Nordisk Says White House Obesity Plan Is Step in Right Direction (The Wall Street Journal)
02:11PM	Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal (GuruFocus.com)
01:49PM	Medicare Could Pay for Wegovy. Dont Count On It. (Barrons.com)
01:28PM	Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations (Investopedia)
01:26PM	Amgen Stock Dives After Weight-Loss Drug Data. Heres What to Know. (Barrons.com)
01:04PM	Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment (Investor's Business Daily)
12:44PM	Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs (Investopedia)
12:33PM	Biden Proposal to Cover Obesity Drugs Sets Up Quandary for Trump (Bloomberg)
12:03PM	Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More (Investopedia)
11:31AM	Amgen Falls as Weight-Loss Shot Results Disappoint Street (Bloomberg)
10:17AM	Amgen Obesity Drug Cut Weight In Closely Watched Study (The Wall Street Journal)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zakrowski Donald A	Officer	Nov 08 '24	Proposed Sale	803.38	900	723,042		Nov 08 04:54 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 08 '24	Sale	803.38	900	723,042	5,480	Nov 08 04:18 PM
Montarce Lucas	EVP & CFO	Nov 01 '24	Option Exercise	0.00	1,074	0	11,541	Nov 05 04:15 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Nov 01 '24	Option Exercise	0.00	1,687	0	31,369	Nov 05 04:14 PM
Dozier Eric	EVP, HR & Diversity	Nov 01 '24	Option Exercise	0.00	1,534	0	8,724	Nov 05 04:13 PM
LILLY ENDOWMENT INC	10% Owner	Sep 03 '24	Sale	966.69	24,084	23,281,840	96,891,978	Sep 04 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 27 '24	Sale	968.46	24,552	23,777,668	96,916,062	Aug 28 04:05 PM
Zakrowski Donald A	Officer	Aug 26 '24	Proposed Sale	950.00	750	712,500		Aug 26 04:47 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 26 '24	Sale	950.00	750	712,500	6,380	Aug 26 04:21 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Sale	966.33	3,196	3,088,382	96,940,614	Aug 23 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Proposed Sale	951.97	215,000	204,673,550		Aug 22 12:54 PM
LILLY ENDOWMENT INC	10% Owner	Jul 10 '24	Sale	939.82	210,000	197,361,398	96,943,810	Jul 11 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 08 '24	Sale	918.64	93,593	85,977,954	97,153,810	Jul 09 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 05 '24	Sale	915.18	52,369	47,927,194	97,247,403	Jul 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 03 '24	Sale	915.31	8,848	8,098,655	97,299,772	Jul 03 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 01 '24	Sale	915.26	58,749	53,770,776	97,308,620	Jul 02 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 28 '24	Sale	915.02	1,441	1,318,545	97,367,369	Jul 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 25 '24	Sale	903.82	188,100	170,009,262	97,368,810	Jun 26 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 24 '24	Sale	902.38	17,229	15,547,068	97,556,910	Jun 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 20 '24	Sale	902.67	9,671	8,729,733	97,574,139	Jun 21 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 17 '24	Sale	885.91	194,978	172,733,708	97,583,810	Jun 18 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 14 '24	Sale	882.47	15,022	13,256,490	97,778,788	Jun 17 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 10 '24	Sale	860.78	75,510	64,997,274	97,793,810	Jun 11 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 07 '24	Sale	852.29	139,490	118,886,587	97,869,320	Jun 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 06 '24	Sale	837.82	179,617	150,485,878	98,008,810	Jun 07 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 05 '24	Sale	836.32	20,383	17,046,673	98,188,427	Jun 06 04:00 PM
Rau Diogo	EVP & CIDO	Jun 01 '24	Option Exercise	0.00	6,300	0	14,146	Jun 04 04:14 PM
LILLY ENDOWMENT INC	10% Owner	Jun 03 '24	Sale	829.77	192,794	159,974,050	98,208,810	Jun 04 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Jun 03 '24	Sale	819.47	750	614,602	7,130	Jun 03 04:15 PM
Norton Johna	EVP, Global Quality	Jun 03 '24	Sale	819.38	7,056	5,781,545	25,428	Jun 03 04:14 PM
LILLY ENDOWMENT INC	10% Owner	May 31 '24	Sale	822.11	22,206	18,255,871	98,401,604	Jun 03 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 29 '24	Sale	811.04	130,385	105,747,975	98,423,810	May 30 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 28 '24	Sale	809.00	2,052	1,660,068	98,554,195	May 29 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 24 '24	Sale	809.21	92,563	74,902,998	98,556,247	May 28 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 23 '24	Sale	809.99	50,767	41,120,963	98,648,810	May 24 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 22 '24	Sale	804.18	12,974	10,433,483	98,699,577	May 23 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 21 '24	Sale	805.45	186,259	150,021,694	98,712,551	May 22 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Mar 11 '24	Sale	753.60	750	565,200	7,880	Mar 11 04:27 PM
LILLY ENDOWMENT INC	10% Owner	Feb 16 '24	Sale	780.99	169,684	132,521,930	98,898,810	Feb 20 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 15 '24	Sale	760.46	50,316	38,263,417	99,068,494	Feb 16 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 09 '24	Sale	740.60	206,257	152,753,428	99,118,810	Feb 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 08 '24	Sale	740.06	8,743	6,470,336	99,325,067	Feb 09 04:05 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '24	Option Exercise	0.00	4,442	0	26,631	Feb 02 04:32 PM
Yuffa Ilya	EVP & President, LLY Int'l	Feb 01 '24	Option Exercise	0.00	3,702	0	16,676	Feb 02 04:29 PM
Ricks David A	President, Chair, and CEO	Feb 01 '24	Option Exercise	0.00	29,611	0	455,054	Feb 02 04:28 PM
Jonsson Patrik	EVP&Pres, LLY Dia&Obe, LLY USA	Feb 01 '24	Option Exercise	0.00	4,124	0	41,065	Feb 02 04:26 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 01 '24	Option Exercise	0.00	9,941	0	115,262	Feb 02 04:25 PM
Norton Johna	EVP, Global Quality	Feb 01 '24	Option Exercise	0.00	1,268	0	31,382	Feb 02 04:24 PM
Van Naarden Jacob	EVP & Pres., Loxo@Lilly	Feb 01 '24	Option Exercise	0.00	3,618	0	15,463	Feb 02 04:22 PM
White Anne E.	EVP & Pres, Lilly Neuroscience	Feb 01 '24	Option Exercise	0.00	4,124	0	62,050	Feb 02 04:20 PM
LILLY ENDOWMENT INC	10% Owner	Jan 31 '24	Sale	648.07	78,573	50,920,924	99,333,810	Feb 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 30 '24	Sale	645.22	76,215	49,175,200	99,412,383	Jan 31 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 29 '24	Sale	645.07	54,032	34,854,422	99,488,598	Jan 30 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 16 '24	Sale	645.60	1,180	761,806	99,542,630	Jan 17 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 11 '24	Sale	634.13	12,344	7,827,686	99,543,810	Jan 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 10 '24	Sale	630.59	163,730	103,246,373	99,556,154	Jan 11 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 09 '24	Sale	631.81	34,538	21,821,413	99,719,884	Jan 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 04 '24	Sale	630.28	14,388	9,068,445	99,754,422	Jan 05 02:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LLY

Lilly(Eli) & Co

Upgrade your FINVIZ experience